《新生儿黄疸的诊断和治疗》由会员分享，可在线阅读，更多相关《新生儿黄疸的诊断和治疗（5页珍藏版）》请在金锄头文库上搜索。
1、The LancetVolume 375, Issue 9729, Pages 1845-1938 (29 May 2010-4 June 2010)Editorial1.Detection and treatment of neonatal jaundice新生儿黄疸的诊断和治疗2.Postnatal depression: fathers have it too产后抑郁症：父亲亦有3.Attention to HIV prevention in Asia Pacific亚洲太平洋地区关注艾滋病毒预防Comment4.Fibrates in CVD: a step towards perso
2、nalised medicine贝特类降血脂药在心血管疾病：走向药物个性化的一步5.Science and politics of heroin prescription海洛因处方的科学与政治6.Are we any closer to combating Ebola infections?我们更接近与埃博拉感染斗争？7.Age and the epidemiology and pathogenesis of tuberculosis肺结核病发病机制以及发病年龄和流行病学8.A UK strategy for mental health and wellbeing英国关于心理健康和福利的战略9
3、.The neurobiology of maltreatment and adolescent violence青少年暴力和虐待的神经生物学10.Offline: The kingmakers of health离线：健康的拥立者World Report11.UN raises priority of non-communicable diseases联合国提出非传染性疾病的优先权12.Hospital train provides lifeline to rural India火车医院为印度农村地区提供了生命线13.USA and North Korea work together on
4、tuberculosis美国和朝鲜共同致力于结核病治疗Perspectives14.Neurology and the power of naming神经病学和命名权15.Hit and misshospital dramas on TV碰运气医院电视连续剧16.What are my chances, doc?什么是我的机会，医生？17.Carla Boutin-FosterCarla Boutin-Foster：纽约威尔康乃尔医学院社区参与差距研究中心18.Moral panic and pandemics道德恐慌和流行病Obituary19.Alan John Flisher讣告：Ala
5、n John Flisher（有影响力的南非儿童和青少年精神病学家）Correspondence20.Measuring concurrent partnerships一致的伙伴关系的测量21.Measuring concurrent partnerships一致的伙伴关系的测量22.Measuring concurrent partnerships Authors reply一致的伙伴关系的测量作者回复23.Anthracycline-based adjuvant chemotherapy in breast cancer乳腺癌患者的蒽环类为基础的辅助化疗24.Anthracycline-b
6、ased adjuvant chemotherapy in breast cancer乳腺癌患者的蒽环类为基础的辅助化疗25.Anthracycline-based adjuvant chemotherapy in breast cancer Authors reply乳腺癌患者的蒽环类为基础的辅助化疗作者回复26.Withholding access to research data拒绝研究数据的获取27.Withholding access to research data Authors reply拒绝研究数据的获取作者回复28.Antimicrobial drugs for Burul
7、i ulcer布鲁里溃疡的抗菌药物29.Antimicrobial drugs for Buruli ulcer Authors reply布鲁里溃疡的抗菌药物作者回复30.Research capacity strengthening in African countries加强非洲国家的研究能力Articles31.Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis贝特类降血脂药对心血管影响的结果：系统性回顾和荟萃分析Min Jun, Celine Foote, Jich
8、eng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado PerkovicSummaryBackground Several clinical trials have reported inconsistent findings for the effect of fibrates on cardiovascular risk. We undertook a systematic review and meta-analysis to i
9、nvestigate the effects of fibrates on major clinical outcomes.Methods We systematically searched Medline, Embase, and the Cochrane Library for trials published between 1950 and March, 2010. We included prospective randomised controlled trials assessing the effects of fibrates on cardiovascular outco
10、mes compared with placebo. Summary estimates of relative risk (RR) reductions were calculated with a random effects model. Outcomes analysed were major cardiovascular events, coronary events, stroke, heart failure, coronary revascularisation, all-cause mortality, cardiovascular death, non-vascular d
11、eath, sudden death, new onset albuminuria, and drug-related adverse events.Findings We identified 18 trials providing data for 45 058 participants, including 2870 major cardiovascular events, 4552 coronary events, and 3880 deaths. Fibrate therapy produced a 10% RR reduction (95% CI 018) for major ca
12、rdiovascular events (p=0048) and a 13% RR reduction (719) for coronary events (p00001), but had no benefit on stroke (3%, 16 to 9; p=069). We noted no effect of fibrate therapy on the risk of all-cause mortality (0%, 8 to 7; p=092), cardiovascular mortality (3%, 7 to 12; p=059), sudden death (11%, 6
13、 to 26; p=019), or non-vascular mortality (10%, 21 to 05; p=0063). Fibrates reduced the risk of albuminuria progression by 14% (225; p=0028). Serious drugrelated adverse events were not significantly increased by fibrates (17 413 participants, 225 events; RR 121, 091161; p=019), although increases i
14、n serum creatinine concentrations were common (199, 146270; p00001).Interpretation Fibrates can reduce the risk of major cardiovascular events predominantly by prevention of coronary events, and might have a role in individuals at high risk of cardiovascular events and in those with combined dyslipi
15、daemia.32.Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial在英格兰慢性海洛因成瘾者正统治疗持续失败后海洛因注射监督或美沙酮注射与优化的美沙酮口服方案治疗的效果（RIOTT）：随机试验RIOTT：Randomised Injectable Opiate Treatment TrialJohn Strang, Nicola Metrebian, Nicholas Lintzeris, Laura Potts, Tom Carnwath, Soraya Mayet, Hugh Williams, Deborah Zador, Richard Evers, Teodora Groshkova, Vikki Charles, Anthea Martin, Luci
